Pfizer (NYSE: PFE) CEO receives 1,630 phantom stock units award

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Pfizer Inc. reported that Chairman and CEO Albert Bourla acquired 1,630 phantom stock units linked to Pfizer common stock. The units were granted at a reference price of $26.58 per unit under the Pfizer Nonfunded Deferred Compensation and Supplemental Savings Plan.

Each unit tracks one share of common stock but is settled in cash after his separation from service rather than in actual shares. Following this grant, Bourla holds a total of 759,400 phantom stock units, providing cash-based exposure to Pfizer’s share value as part of his long-term compensation.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider BOURLA ALBERT

Role Chairman & CEO

Type	Security	Shares	Price	Value
Grant/Award	Phantom Stock Units SSP	1,630	$26.58	$43K

Holdings After Transaction: Phantom Stock Units SSP — 759,400 shares (Direct)

Footnotes (1)

Each unit represents one phantom share of common stock. These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

Form 4 Insider Transactions: What Each Field Means →

03/16/2026 - 05:45 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BOURLA ALBERT

(Last)

(First)

(Middle)

66 HUDSON BOULEVARD EAST

ATTN: CORPORATE SECRETARY

(Street)

NEW YORK

10001-2192

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
PFIZER INC [ PFE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chairman & CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Phantom Stock Units SSP	⁽¹⁾	03/13/2026		A		1,630		⁽²⁾	⁽²⁾	Common Stock	1,630	$26.58	759,400	D

Explanation of Responses:

1. Each unit represents one phantom share of common stock.

2. These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

	/s/ Shanice A. Reid, by power of atty., for Albert Bourla	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Pfizer (PFE) report for CEO Albert Bourla?

Pfizer reported that CEO Albert Bourla received 1,630 phantom stock units as a compensation award. Each unit tracks one share of Pfizer common stock and forms part of his deferred compensation, increasing his total phantom unit holdings to 759,400 after this grant.

What are the phantom stock units reported in Pfizer (PFE) CEO’s Form 4?

The phantom stock units are cash-settled awards, each representing one phantom share of Pfizer common stock. They track the value of Pfizer shares but are not actual stock; instead, they are paid in cash following Albert Bourla’s separation from service with the company.

At what reference price were Albert Bourla’s Pfizer (PFE) phantom units granted?

Albert Bourla’s 1,630 phantom stock units were granted at a reference price of $26.58 per unit. This price is used to value the award under the nonfunded deferred compensation plan and helps determine the notional value tied to Pfizer’s common stock.

How many phantom stock units does Pfizer (PFE) CEO Albert Bourla hold after this transaction?

After the latest grant of 1,630 phantom stock units, Albert Bourla holds 759,400 phantom units in total. These units mirror Pfizer’s common stock value and are designed to be settled in cash once he separates from service, aligning compensation with share performance.

How and when are Pfizer (PFE) phantom stock units for Albert Bourla settled?

The phantom stock units are settled in cash after Albert Bourla’s separation from service with Pfizer. They are issued under the company’s Nonfunded Deferred Compensation and Supplemental Savings Plan and may be moved into an alternative investment account by him at any time.